Insider buying last 90 days
No open-market insider purchases were filed for ALNY in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ALNY insider filing, plotted on the chart in Gekko.Open ALNY in Gekko
NASDAQ: ALNY
Alnylam Pharmaceuticals (ALNY) Stock Analysis & Forecast
$239.56−5.95 (−2.4%)
Close on Sep 18, 2026. Page updated Sep 19, 9:19 pm ET.
Gekko Brief
AI summaryAlnylam shares close at $239.56, down 2.4% on the day and below both the 50-day ($247.94) and 200-day ($312.17) moving averages, with the shorter average sitting under the longer one. The stock has fallen 13.9% over three months and 23% over six months, and sits well off its 52-week high of $495.55 while still above its 52-week low of $197.81. The GekkoIndex reads 61.7, placing ALNY in the Accumulation zone, and the current price is 19.3% below the Gekko Fair Value of $296.89.
Recent coverage centers on zilebesiran, an investigational RNAi therapy aimed at twice-yearly blood-pressure control for patients with uncontrolled hypertension, discussed in the ZENITH trial strategy and a related transcript. Separate commentary notes that despite a steep sell-off, Wall Street sentiment remains bullish, pointing to two recent developments described as improving the competitive landscape.
The next earnings report is scheduled for 29 October 2026, before the open, 39 days away and outside a typical 20-trading-day holding window; the last report on 30 July showed EPS of -$0.52 against a $1.44 estimate, with an 8% average absolute reaction historically and a -28.3% move after that release. Options activity shows 1 unusual signal in the last 30 days, with call premium of $2,539,715 and no put premium. Analyst coverage stands at 19 buy and 3 hold ratings among 22 firms, with a consensus target of $371.35. Seasonality over the past 5 years shows an average 20-day return of 2.4%, positive in 3 of those years.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $239.56200-day averageGekko Fair Value $296.89
Key stats
- Market cap
- $32.06B
- P/E ratio
- 41.7
- Forward P/E
- 18.7
- EPS, TTM
- $5.89
- Revenue, TTM
- $4.80B
- Profit margin
- 16.1%
- Dividend yield
- —
- Beta
- 0.30
- Volume
- 2.73M avg 1.65M
- 1-year return
- −47.0%
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±7%
- 50-day average
- $247.94
- 200-day average
- $312.17
- Next earnings
- Oct 29 before open
- Shares outstanding
- 133.8M
Alnylam Pharmaceuticals swing-trade checklist
Alnylam Pharmaceuticals scores 5 supportive, 0 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive0 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $239.56 is below the 50-day ($247.94) and 200-day ($312.17) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
61.7, Accumulation
Reading 61.7 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
19.3% below
Price is 19.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 39 days
Next report Oct 29, 2026, 39 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.4% on average
From this point in the calendar, the next 20 trading days averaged +2.4% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Alnylam Pharmaceuticals stock chart and price history
Alnylam Pharmaceuticals closed at $239.56 on Sep 18, 2026, −47.0% over the past year, inside a 52-week range of $197.81 to $495.55.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.3%
- 3 months
- −13.9%
- 6 months
- −23.0%
- 1 year
- −47.0%
The full ALNY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ALNY in Gekko
Follow Alnylam Pharmaceuticals through every session
Put ALNY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ALNY in GekkoFree for 7 days. No credit card required.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals works in medicine built around RNA interference, a technique used to silence disease-causing genes. The company turns this science into treatments for conditions such as inherited genetic disorders, cardio-metabolic disease, liver infections, and disorders of the nervous system and eyes. It has brought three therapies to market: ONPATTRO for nerve damage linked to hereditary transthyretin amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for a rare kidney condition called primary hyperoxaluria type 1.
Alongside these approved products, Alnylam runs a pipeline of experimental treatments targeting conditions including hepatitis B, high cholesterol, hemophilia, hypertension, liver disease linked to AAT deficiency, and NASH, with several candidates in later-stage trials. Much of this work is carried out through partnerships, including research alliances with Regeneron and Sanofi Genzyme, plus additional licensing arrangements with companies such as Novartis, Vir Biotechnology, Dicerna, Ionis and PeptiDream.
The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker ALNY.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- alnylam.com
Alnylam Pharmaceuticals GekkoIndex: the smart money zone
Alnylam Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.7, in the Accumulation zone, up 2 points over five sessions.
61.7Accumulation
Up 2 points over five sessions, from the Neutral zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 45 | +0.2% | −4.3% |
| Accumulation (current zone) | 266 | 0.0% | −0.2% |
| Neutral | 305 | +0.9% | +5.2% |
| Distribution | 33 | −0.5% | −0.8% |
| Selling | 13 | +4.0% | +0.6% |
Average ALNY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ALNY price, zone by zone.Track ALNY in Gekko
Is Alnylam Pharmaceuticals stock overvalued? Gekko Fair Value
Alnylam Pharmaceuticals trades 19.3% below Gekko Fair Value of $296.89, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Alnylam Pharmaceuticals shares are worth, recalculated every trading day.
$296.89
Gekko Fair Value, Sep 19, 2026
19.3% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open ALNY in Gekko
Alnylam Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Alnylam Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ALNY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ALNY, plotted on the chart in Gekko.Open ALNY in Gekko
Buybacks
Alnylam Pharmaceuticals has been buying back its own shares.
- Bought back, year ended Dec 31, 2018
- $3.47M
- As a share of market cap
- 0.01%
From company filings.
Unusual options activity last 30 days
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Sep 3, $2.54M in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold ALNY.
0added2opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Alnylam Pharmaceuticals earnings: next date and track record
Alnylam Pharmaceuticals reports on Oct 29, 2026, before the open (39 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Oct 29, 2026
Expected before the open, 39 days away
- EPS estimate
- $1.77
- Revenue estimate
- $1.43B
6 of 8reports beat the EPS estimate
±8%average move across the report
1 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 30, 2026 AI summary
- What they said
- Alnylam reported strong Q2 performance driven by the AMVUTTRA ATTR-CM launch, with total net product revenues approx. $1.2 billion (up 74% YoY) and TTR revenues exceeding $1 billion in a single quarter for the first time. Management highlighted robust first-line uptake, broad access, >90% adherence, geographic expansion (China collaboration with BeOne subject to approval), and continued investment in R&D (including multiple Phase III programs such as ZENITH for zilebesiran and TRITON-CM for nucresiran). The company announced it is lowering 2026 revenue guidance (new range $4.2B–$4.5B) but reiterated confidence in long-term 2030 ambitions (25% CAGR target). Financials included higher royalties (pressuring gross margin to 75%), increased R&D and SG&A spend, and continued royalty and collaboration revenue growth. Management emphasized clinical strength of AMVUTTRA (HELIOS-B outcomes), conviction in nucresiran’s potential, and plans to expand prescriber base and diagnosis efforts. During Q&A management acknowledged lowering guidance, explained drivers (inventory phasing, pricing dynamics, increased royalties, normalization of second-line switches), and expressed measured confidence in near- and long-term growth despite the guidance revision.
- Guidance
- Lowered 2026 revenue guidance to $4.2 billion - $4.5 billion (midpoint discussed). Reaffirmed long-term Alnylam 2030 ambition (25% CAGR). Expectation of continuing modest quarter-to-quarter net price decreases and a mid-single-digit net price decline year-over-year. No other numeric EPS or margin guidance provided on the call.
- Risks flagged
- Lowered 2026 guidance reflects near-term uncertainties (inventory phasing, net price pressures, higher royalty burden). Other risks discussed or implied: potential payer pushback or coverage changes, competitive dynamics (other silencers/stabilizers and a recent competitor trial), genericization of tafamidis in Europe impacting dynamics, reliance on successful outcomes from ongoing Phase III studies (TRITON-CM, ZENITH), and operational execution risks in expanding prescriber base and global rollouts.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | −$0.52 est $1.44 | $1.29B est $1.32B | −28.3% |
| Apr 30, 2026 | $1.99 est $1.47 | $1.17B est $1.12B | −1.7% |
| Feb 12, 2026 | $1.25 est $1.24 | $1.10B est $1.15B | −2.4% |
| Oct 30, 2025 | $2.90 est $0.56 | $1.25B est $959.4M | −5.3% |
| Jul 31, 2025 | $0.32 est −$0.54 | $773.7M est $662.9M | +18.2% |
| May 1, 2025 | −$0.01 est −$0.89 | $594.2M est $585.1M | −1.5% |
| Feb 13, 2025 | $0.06 est −$0.14 | $593.2M est $582.6M | −3.6% |
| Oct 31, 2024 | −$0.50 est −$0.39 | $500.9M est $532.9M | −2.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Alnylam Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Alnylam Pharmaceuticals is $371.35, +55.0% from the last close, from 22 firms rating the stock in the last 90 days.
$371.35consensus 12-month target, +55.0% from the last close
Now $239.56Avg $371.35
Low $256High $550
Each firm’s latest rating in the last 90 days: 22 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | Truist Financial | — | — |
| Sep 17 | Needham | $357 | +49.0% |
| Sep 17 | BMO Capital | $318 | +32.7% |
| Sep 16 | Bernstein | $376 | +57.0% |
| Sep 11 | Morgan Stanley | $300 | +25.2% |
−0.2%average 20-day move after past Accumulation readings
+2.4%average move over the next 20 trading days in the last 5 years
±4.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Alnylam Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, Alnylam Pharmaceuticals averaged +2.4% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.0% | 1 of 5 |
| Next 10 trading days | −0.8% | 2 of 5 |
| Next 15 trading days | −1.0% | 2 of 5 |
| Next 20 trading days | +2.4% | 3 of 5 |
| Next 30 trading days | −4.7% | 2 of 5 |
For scale, ALNY’s typical 20-trading-day move in either direction is about 7%.
Alnylam Pharmaceuticals market cap and key statistics
Alnylam Pharmaceuticals’s market cap is $32.06B, with a P/E ratio of 41.7 and revenue of $4.80B over the last twelve months.
Valuation
- Market cap
- $32.06B
- P/E ratio
- 41.7
- Forward P/E
- 18.7
- EPS, TTM
- $5.89
- Gekko Fair Value
- $296.89
Trading
- Volume
- 2.73M
- Avg volume, 20 days
- 1.65M
- 52-week high
- $495.55
- 52-week low
- $197.81
- Shares outstanding
- 133.8M
Financials
- Revenue, TTM
- $4.80B
- Profit margin
- 16.1%
- Return on equity
- 96.6%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.30
- Typical daily move
- ±4.5%
- Typical 20-day move
- ±7%
Alnylam Pharmaceuticals stock news this week
3 headlines about Alnylam Pharmaceuticals from the past week, newest first, each linking to the publisher.
- Alnylam's Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH TrialMarketBeat, Sep 19
- Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Zilebesiran and the Potential of RNAi Therapeutics for Continuous Blood Pressure Control TranscriptSeeking Alpha, Sep 17
- Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter PictureThe Motley Fool, Sep 15
Alnylam Pharmaceuticals peers
Alnylam Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Accumulation | 15.7% above |
| JNJJohnson & Johnson | Neutral | 2.7% below |
| ABBVAbbVie | Neutral | 22.6% above |
| MRKMerck | Neutral | 7.3% below |
| AZNAstraZeneca | Neutral | 41.0% below |
| PFEPfizer | Neutral | 9.8% below |
A peer links to its own page where one exists.
Alnylam Pharmaceuticals stock FAQ
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $32.06B at the Sep 18, 2026 close of $239.56, with 133.8M shares outstanding. The shares trade on a P/E ratio of 41.7.
What is the Alnylam Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Alnylam Pharmaceuticals is $371.35, +55.0% from the last close. Of the 22 firms that rated the stock in the last 90 days, 19 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Alnylam Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Alnylam Pharmaceuticals is undervalued: the Sep 18, 2026 close of $239.56 is 19.3% below Gekko Fair Value of $296.89. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Alnylam Pharmaceuticals report earnings next?
Alnylam Pharmaceuticals is expected to report on Oct 29, 2026, before the market opens (39 days away). Analysts expect earnings of $1.77 per share on revenue of $1.43B. Alnylam Pharmaceuticals beat the earnings estimate in 6 of its last 8 reports, moving 8% on average across the report.
What is Alnylam Pharmaceuticals’s 52-week high and low?
Alnylam Pharmaceuticals’s 52-week high is $495.55 and its 52-week low is $197.81; it closed at $239.56 on Sep 18, 2026, −47.0% over the past year.
Is Alnylam Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (gekkoindex, fair value, smart money, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Alnylam Pharmaceuticals?
Gekko flagged 1 unusual options signal in Alnylam Pharmaceuticals over the last 30 days, with $2.54M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Sep 3, 2026 with $2.54M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Alnylam Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.